CorMedix Inc (CRMD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $370.64M
Last updated: Nov 17, 2026 at 11:05 AM ET
CorMedix Inc (CRMD) Competitors
The companies most similar to CorMedix are DiaMedica Therapeutics (DMAC), CytomX Therapeutics (CTMX) and MiMedx Group (MDXG). By market cap, CorMedix ranks 7th of the 13 companies on this page; Immix Biopharma (IMMX) is the largest at $657.09M.
Peer Comparison
CRMD's ROIC of 13.9% is above the peer median of -38.3%, and its revenue growth of -47.7% is below the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| CorMedix (CRMD) | $370.64M | 6.3x | 0.9x | 15.5% | 13.9% | -47.7% | 0.00% |
| DiaMedica Therapeutics Inc (DMAC) | $474.29M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| CytomX Therapeutics Inc (CTMX) | $444.73M | N/A | 31.0x | 0.0% | -32.8% | -71.7% | 0.00% |
| MiMedx Group Inc (MDXG) | $468.42M | 106.0x | 1.5x | -6.3% | N/A | -45.2% | 0.00% |
| Immix Biopharma Inc (IMMX) | $657.09M | N/A | N/A | 0.0% | -14.9% | 0.0% | 0.00% |
| Immuneering Corp (IMRX) | $240.27M | N/A | N/A | 0.0% | N/A | -99.8% | 0.00% |
| Contineum Therapeutics, Inc. Class A Common Stock (CTNM) | $387.16M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Rezolute Inc (RZLT) | $353.54M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Editas Medicine Inc (EDIT) | $334.92M | N/A | 5.6x | -145.0% | -42.3% | 37.4% | 0.00% |
| Fulcrum Therapeutics Inc (FULC) | $287.96M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Orchestra BioMed Holdings Inc. (OBIO) | $570.61M | N/A | 14.7x | -182.5% | -97.0% | -89.4% | 0.00% |
| Precision BioSciences Inc (DTIL) | $288.76M | N/A | 4.4x | -85.6% | -38.3% | 37272.0% | 0.00% |
| Protalix Biotherapeutics Inc (PLX) | $257.17M | 12.1x | 2.9x | 24.3% | N/A | 22.8% | 0.00% |
| Peer median | $370.35M | 59.0x | 5.0x | 0.0% | -38.3% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to CorMedix, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| DiaMedica Therapeutics Inc (DMAC) | DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. | DMAC competitors |
| CytomX Therapeutics Inc (CTMX) | CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. | CTMX competitors |
| MiMedx Group Inc (MDXG) | MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company is headquartered in Marietta, Georgia. | MDXG competitors |
| Immix Biopharma Inc (IMMX) | Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology... | IMMX competitors |
| Immuneering Corp (IMRX) | Immuneering Corp (IMRX) is a cutting-edge biotechnology firm dedicated to advancing targeted therapeutics for cancer and other critical illnesses through its... | IMRX competitors |
| Contineum Therapeutics, Inc. Class A Common Stock (CTNM) | Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies... | CTNM competitors |
| Rezolute Inc (RZLT) | Rezolute, Inc., a clinical-stage biopharmaceutical company, develops rare and metabolic disease therapies in the United States. | RZLT competitors |
| Editas Medicine Inc (EDIT) | Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. | EDIT competitors |
| Fulcrum Therapeutics Inc (FULC) | Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined... | FULC competitors |
| Orchestra BioMed Holdings Inc. (OBIO) | Orchestra BioMed Holdings, Inc. is a therapeutic device company that develops therapeutic treatments and products for cardiovascular diseases. | OBIO competitors |
| Precision BioSciences Inc (DTIL) | Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. | DTIL competitors |
| Protalix Biotherapeutics Inc (PLX) | Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its... | PLX competitors |
Frequently Asked Questions About CRMD
Who are CorMedix's main competitors?
The companies most similar to CorMedix include DiaMedica Therapeutics (DMAC), CytomX Therapeutics (CTMX), MiMedx Group (MDXG), Immix Biopharma (IMMX) and Immuneering (IMRX), listed from the closest match.
Who is CorMedix's biggest competitor?
Immix Biopharma (IMMX) is the largest of the similar companies at $657.09M; DiaMedica Therapeutics (DMAC) is the closest match by business profile, size, sector and industry.
How does CRMD stock compare with its competitors?
CRMD's P/E is 6.3x against a peer median of 59.0x; its P/S is 0.9x against a peer median of 5.0x; its net margin is 15.5% against a peer median of 0.0%.
Which of CorMedix's competitors pays a higher dividend?
CorMedix pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is CorMedix bigger than its competitors?
No. CorMedix is 7th by market cap among the 13 companies on this page; the largest is Immix Biopharma (IMMX) at $657.09M.
CRMD pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors